Related Experiment Video
Updated: Jun 19, 2025

Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
Published on: December 15, 2023
Exceptional performance with minimal data using a generative adversarial network for alzheimer's disease
Pui Ching Wong1, Shahrum Shah Abdullah2, Mohd Ibrahim Shapiai3
1Biologically Inspired System and Technology Laboratory, Department of Electronic Systems Engineering, Malaysia-Japan International Institute of Technology, Universiti Teknologi Malaysia, Kuala Lumpur, Malaysia. puiching1997@graduate.utm.my.
Abstract:
The classification of Alzheimer's disease (AD) using deep learning models is hindered by the limited availability of data. Medical image datasets are scarce due to stringent regulations on patient privacy, preventing their widespread use in research. Moreover, although open-access databases such as the Open Access Series of Imaging Studies (OASIS) are available publicly for providing medical image data for research, they often suffer from imbalanced classes. Thus, to address the issue of insufficient data, this study proposes the integration of a generative adversarial network (GAN) that can achieve comparable accuracy with a reduced data requirement. GANs are unsupervised deep learning networks commonly used for data augmentation that generate high-quality synthetic data to overcome data scarcity. Experimental data from the OASIS database are used in this research to train the GAN model in generating synthetic MRI data before being included in a pretrained convolutional neural network (CNN) model for multistage AD classification. As a result, this study has demonstrated that a multistage AD classification accuracy above 80% can be achieved even with a reduced dataset. The exceptional performance of GANs positions them as a solution for overcoming the challenge of insufficient data in AD classification.
Related Concept Videos
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Alzheimer's Disease: Treatment

